Aytu BioPharma Q3 net loss $5.6M; EXXUA launch revenue $2.4M

AYTU BIOPHARMA, INC

2026-Q3 EPS reported -$1.42 revenue$41,464,000

Net revenue $12.4M, down 33% YoY from $18.5M; net loss $5.6M vs net income $4.0M.
EXXUA (gepirone) contributed $2.4M net revenue; over 1,300 prescriptions from 450 prescribers in partial quarter.
ADHD Portfolio $9.1M (-41% YoY) due to sales force shift to EXXUA and generic competition for Adzenys XR-ODT.
Adjusted EBITDA -$2.8M vs $3.9M YoY; warrant amendment reduced derivative liabilities by $26.4M, boosting equity.
Cash $26.7M at March 31, 2026, down from $31.0M at June 30, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.